1. Magnesium lithospermate B acts against dextran sodiumsulfate-induced ulcerative colitis by inhibiting activation of the NRLP3/ASC/Caspase-1 pathway
- Author
-
Lan Rong, Xiaoyun Jiang, Liang Zhong, and Dayu Sun
- Subjects
0301 basic medicine ,Male ,Health, Toxicology and Mutagenesis ,Injections, Subcutaneous ,Caspase 1 ,Pharmacology ,Toxicology ,03 medical and health sciences ,Subcutaneous injection ,Mice ,Western blot ,Oral administration ,medicine ,Animals ,Receptor ,Mice, Inbred BALB C ,medicine.diagnostic_test ,business.industry ,Tumor Necrosis Factor-alpha ,Dextran Sulfate ,General Medicine ,medicine.disease ,Ulcerative colitis ,CARD Signaling Adaptor Proteins ,030104 developmental biology ,Gene Expression Regulation ,Immunology ,Tumor necrosis factor alpha ,Colitis, Ulcerative ,business ,Apoptosis Regulatory Proteins ,Carrier Proteins ,Inflammasome complex ,Drugs, Chinese Herbal ,Signal Transduction - Abstract
This study aimed to observe the therapeutic effects of magnesium lithospermate B on acute and chronic colitis induced by dextran sodiumsulfate (DSS) and the role of inflammasome complex (NOD-like receptor protein, NLRP; apoptosis-associated speck-like protein containing, ASC; caspase-1). Establishment of acute and chronic colitis models were by using 5% DSS oral administration in BALB/C male mice. Magnesium lithospermate B (240 mg/kg body weight) was given by subcutaneous injection. Samples were collected for biomarker assay, histological examination, immunohistochemical evaluation and western blot. There was obvious increase in TNF-α level and NLPR3, ASC, and caspase-1 expressions in acute and chronic colitis groups compared with the normal control. Significant decrease of the tumor necrosis factor-α level and the expressions of NLPR3, ASC, and caspase-1 were observed after treatment with magnesium lithospermate B. This study showed that magnesium lithospermate B could be used to treat acute and chronic colitis by inhibiting the activation of the NLRP3/ASC/Caspase-1 pathway.
- Published
- 2015